Fighting Fungal Eye Infections: A New Hope with Intravitreal Caspofungin
"When common antifungals fail, a novel approach offers a beacon of hope for severe eye infections."
Fungal endophthalmitis, a rare but devastating eye infection, typically accounts for 8% to 18% of all culture-positive endophthalmitis cases. Its rarity often translates to a lack of robust, evidence-based treatment strategies, leaving patients with a challenging prognosis.
Traditional treatments sometimes fall short, especially when dealing with resistant strains of fungi. This is where innovative approaches become crucial. The following case report sheds light on a successful intervention using intravitreal caspofungin to combat a particularly stubborn fungal infection.
This article will explore the details of a case involving Stephanoascus ciferrii, an unusual yeast-like fungus, and how it was effectively treated with intravitreal caspofungin. This case offers a promising alternative when conventional antifungal therapies prove ineffective.
How Fungal Infections Reach the Eye
The CDC distinguishes exogenous fungal endophthalmitis, which follows fungal spores entering the eye from an external source, from endogenous disease, in which a bloodstream infection such as candidemia spreads to one or both eyes. Many fungi can cause eye infections; Fusarium lives in the environment, especially in soil and on plants. A 2024 single-center study reported that 60% of Candida infections and 75% of culture-negative endogenous fungal endophthalmitis cases were initially treated with oral antifungals. Patients with immune compromise, positive fungal cultures, or positive Fungitell assays were more likely to receive early intravenous antifungal therapy.
The Case: Beating a Resistant Fungal Infection
In October 2014, a 57-year-old woman sought help at an eye clinic two weeks after undergoing cataract surgery. Her vision had deteriorated significantly. An examination revealed ciliary injection, numerous cells in the anterior chamber, and a small hypopyon, indicating a severe inflammatory response. Initial treatments with vancomycin were administered, but her condition continued to worsen.
- Initial Symptoms: Ciliary injection, anterior chamber inflammation, hypopyon.
- Diagnosis: Stephanoascus ciferrii, resistant to common antifungals.
- Failed Treatments: Vancomycin, fluconazole, voriconazole, amphotericin B.
Caspofungin Evidence Remains Limited
A case-report review notes that Danielescu et al. increased intravitreal caspofungin to 250 μg after recurrences. A 2026 report on Scopulariopsis fungal endophthalmitis says prior reports suggest reasonable intraocular tolerability, safety, and potential utility for caspofungin and micafungin in multidrug-resistant mold infections. It also stresses that available data are limited, dosing is not standardized, and human clinical experience is sparse. A separate rabbit study examined potential nephrotoxic effects following intravitreal voriconazole and micafungin, rather than caspofungin.
Different Treatments for Different Ocular Infections
A 2019 review describes natamycin (Natacyn® eye drops) as the only approved medication for ocular fungal infections. A 2026 article calls natamycin the gold standard and says compounded voriconazole, amphotericin B, and fluconazole can be alternatives when it is unavailable. These sources discuss ocular fungal infections broadly, while a 2026 review of endogenous fungal endophthalmitis emphasizes that treatment strategies vary and that systemic disease markers may influence initial therapy more than ocular findings. That review reports no definitive evidence favoring intravenous over oral systemic therapy and recommends a comprehensive, multidisciplinary approach that considers ocular involvement.
A Glimmer of Hope
This case marks a significant step forward in the treatment of fungal endophthalmitis. It demonstrates that even when faced with drug-resistant fungi, alternative therapies like intravitreal caspofungin can offer a successful outcome.
A Sight-Threatening Condition with Emerging Guidance
Endophthalmitis involves replicating microorganisms invading the eye’s internal structures and provoking an inflammatory response, and it carries a risk of permanent visual loss. Fungal endophthalmitis remains a major clinical challenge because it is rare, can have delayed onset, and has complex pathology. In December 2025, a global expert panel from the Asia-Pacific region issued 20 consensus statements on diagnosis and management. A 20-eye single-center retrospective study notes that its treatment discussion points are limited by the small sample and absence of a defined protocol.
Host-Directed Research and Market Trends
A May 2026 review proposes that immunomodulatory therapies could move ocular fungal infection treatment beyond pathogen-targeted approaches toward more precise, host-directed interventions. The review identifies complex ocular immunopathology and the logistical hurdles of clinical trials as challenges. Market reports also point to growing attention to awareness, diagnosis, and treatment options, with one report identifying increased awareness of blindness risk as a key future trend. Another projects that over 55% of companies will focus on innovative treatments and diagnostic technologies.
Systemic Disease Complicates Eye Treatment
Endogenous fungal endophthalmitis can occur when a bloodstream infection spreads to the eye, linking ocular disease to systemic infection. Management challenges include a lack of clear guidance on choosing specific intravenous or oral agents and on when to transition systemic treatment based on ophthalmic examination. The use of systemic or intravitreal corticosteroids as an adjunct to reduce inflammation is controversial, because of concerns about how corticosteroids may affect the immune response to fungal infection. Fungal infections also pose a broader public-health concern, particularly for immunocompromised people, including those undergoing chemotherapy or organ transplantation and people living with HIV/AIDS.
Vision Loss and Unequal Access to Care
Fungal keratitis is described as one of the most severe corneal infections because diagnosis and treatment are difficult, and it can have a profound effect on visual quality. A 2022 article argues that fungal keratitis should be recognized as a neglected tropical disease to support awareness, diagnostic capacity, and access to affordable antifungal eye medicine. That article estimates 1,051,787 to 1,480,916 eyes are affected annually and reports that 8–11% of patients have the eye removed. A 2026 case report describes a 35-year-old farmer whose corneal ulcer followed an eye injury from a small stone during farm work; he was successfully managed with therapeutic penetrating keratoplasty.
The successful treatment of Stephanoascus ciferrii endophthalmitis with intravitreal caspofungin provides clinicians with a valuable option when dealing with similar challenging cases. This approach could be considered for patients with fungal eye infections unresponsive to conventional antifungal therapies.
While further research is needed to fully understand the optimal dosage and long-term effects of intravitreal caspofungin, this case offers a beacon of hope for patients facing severe, drug-resistant fungal eye infections, potentially saving their sight and improving their quality of life.